INMUNOTEK has signed a collaboration agreement with IDIPAZ (Instituto de Investigación Hospital Universitario La Paz), through the Fundación para la Investigación Biomédica del Hospital Universitario La Paz, for the study of a new anticancer vaccine.

The research entitled IDENTIFYING THE EFFECTOR MECHANISMS OF THE ANTINEOPLASTIC CA10-BASED VACCINE AND ITS POTENTIAL CLINICAL APPLICATION, directed by Dr. Carlos del Fresno, will be developed over 3 years.

INMUNOTEK has been conducting research for the development of an anti-tumor vaccine based on the tumor carbohydrate Ca10 within the RETOS-Collaboration project with the Hospital Clínico Universitario de Madrid, the Universidad Complutense de Madrid and the CIB-CSIC. The proof-of-concept results obtained in experimental systems have been positive and the aim is to further investigate the mechanisms involved for future clinical translation.

---